Schizophrenia
Conditions
Interventions
Group 1:Active tDCS targeted at the dorsolateral prefrontal cortex
Group 2:Active tDCS targeted at the posterior parietal cortex
Group 3:sham tDCS targeted at the dorsolateral prefrontal cortex or posterior parietal cortex
Sponsors
Beijing Anding Hospital Affiliated to Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1.Patients meeting DSM-5 criteria for schizophrenia; 2.Patients aged 18-50 years, with right handedness, years of education =8; 3.Patients with IQ > 70; 4.Patients with PANSS score at most 5 in the following items: P1 delusion, P3 hallucination, P5 exaggeration, P6 suspicion / victimization, G9 abnormal thinking content; 5.PANSS score at most 4 in the following item: P2 concept disorder; 6.Patients who got T score 30-50 in the spatial span test of MCCB; 7.Patients who are clinically stable, maintained on current antipsychotic and concomitant medications for at least 6 weeks, with no change in antipsychotic dose for at least 2 weeks. Patients must take the same type and dose of antipsychotic medications during the study period.
Exclusion criteria
Exclusion criteria: 1.Patients with cochlear implantation devices or other metal implanted in the body; 2.Patients with color blindness or color weakness; 3.Patients who are pregnant or lactating women; 4.Patients with severe nervous system diseases (history of craniocerebral trauma or infection, brain tumor, cerebrovascular disease, epilepsy, etc.) or other severe physical diseases; 5.Patients with unstable mental state (suicidal intention or impulsive behavior); 6.Patients with a history of alcohol and drug abuse or dependence within 6 months; 7.Patients taking sedative-hypnotic drugs at a dose greater than lorazepam 1 mg / day or equivalent; 8.Patients taking anticholinergic drugs at a dose greater than trihexyphenidyl 10 mg / day or equivalent; 9.Patients taking stimulants (e.g., methylphenidate, dextroamphetamine, modafinil), or receiving electroconvulsive therapy or electromagnetic stimulation or cognitive training within 6 months; 10.Patients receiving repeat assessments using MCCB and/or other cognitive test kits within 12 weeks (i.e., single assessment is not excluded); 11.Patients who are unable or unwilling to cooperate with effective evaluation and treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Spatial span test score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Digit sequencing test scores;n-back scores;DPX scores;change detection scores;change detection task EEG;mismatch negativity;resting-state EEG;MCCB scores;stroop color word test scores;PANSS scores;CDSS scores;Spatial span test score;Color-delayed estimation scores;Adverse effects of tDCS; | — |
Countries
China
Contacts
Public ContactChuanyue Wang
Beijing Anding Hospital Affiliated to Capital Medical University
Outcome results
None listed